Abstract: A bottle holding harness assembly includes a harness to be placed on an upper torso of an adult. The harness has a back side and a front side and a front strap is attached front side of the harness. A saddle is mounted on the front strap. The saddle i releasably receives a bottle and the saddle is rotatable with respect to the front strap.

Abstract: The present application relates to a mouthpiece (20) for an infant feeding vessel (10). The vessel (10) has a mounting collar (60) configured to be received between a receptacle (30) for holding fluid and a connector (40) for mounting the mouthpiece (20) to the receptacle (30) when assembled. The vessel (10) also has an air valve (70) in the mounting collar (60) to allow the flow of air into the receptacle (30) when the mouthpiece (20) is mounted to the receptacle (30). The air valve is biased towards an open condition in its un-assembled state. At least part of the mounting collar (60) is resilient and is configured to be received between the receptacle (30) and the connector (40) when assembled.

Abstract: The present invention provides a dental curable composition used for dental filling restorative materials, dental crown prosthesis materials such as inlays, crowns, and bridges, materials for constructing anchor teeth, block materials for dental CAD/CAM, etc. More specifically, the present invention provides a dental curable composition comprising a curable resin (A), a porous inorganic filler (B), and a polymerization initiator (C), wherein the porous inorganic filler (B) comprises a silicon dioxide, and an oxide comprising at least one kind of the other metallic elements, and a ratio (I1/I2) of a maximum absorbance (I1) of 3730 to 3750 cm?1 to a maximum absorbance (I2) of 3000 to 3600 cm?1 in infrared absorption spectrum of the porous inorganic filler (B), is not less than 2 and not more than 3.

Abstract: A cleaning composition comprising a base and an inorganic particulate material selected from the group consisting of spherical perlite, alumina, vermiculite, nepheline and mixtures thereof, wherein the spherical perlite comprises microspheres that are substantially closed and hollow.

Abstract: Foaming sunscreen compositions of the present invention include a continuous water phase containing from about 0.75% to about 6% of a superhydrophilic amphiphilic copolymer and a discontinuous oil phase dispersed in the water phase, which oil phase contains a UV-absorbing compound, and which foaming sunscreen compositions are essentially free of monomeric surfactants and substantially free of oil soluble polymers.

Abstract: The sunscreen compositions of the present invention include a phase-stable, oil-in-water emulsion that includes a continuous water phase containing a superhydrophilic amphiphilic copolymer and a suspension of styrene/acrylate copolymer particles; and a discontinuous oil phase homogeneously dispersed in the continuous water phase, where the discontinuous oil phase includes a UV absorbing compound and the sunscreen composition is essentially free of monomeric surfactant and has a viscosity of about 2000 cps or less.

Abstract: A formulation for personal hygiene in the form of O/W emulsion with a pH from 5.5 to 6.5, free of surfactants, comprising an emulsifier consisting of a fatty alcohol from 14 to 22 carbon atoms or of Glyceryl Stearate or a mixture thereof, Coco Caprylate and/or Coco Caprylate/Caprate, vitamin E or an ester thereof, and Melaleuca alternifolia oil.

Abstract: The present invention provides nanoparticle compositions including one or more peptides. The present invention achieves transdermal delivery of such peptides without the need for peptide modification, or for use of chemical or mechanical abrasion or disruption of skin.

Abstract: Provided are compounds and compositions thereof that are useful as antioxidants in personal care formulations. The compounds are of the Formula I: wherein R1, R2, R3, R4, and R5 are independently H, —OH, C1-C6 alkoxy, —COOH, —COO?M+ or —O?M+, where M+ is a sodium, potassium, or ammonium ion, and R6, R7, R8, R9, and R10, are independently H, —OH, C1-C6 alkoxy, —COOH, —COO?M+ or —O?M+, where M+ is a sodium, potassium, or ammonium ion, or a substituent of Formula II: wherein R11, R12, R13, R14, and R15 are independently H, —OH, C1-C6 alkoxy, —COOH, —COO?M+ or —O?M+, where M+ is a sodium, potassium, or ammonium ion, provided that one of R6, R7, R8, R9, and R10 is a substituent of Formula II.

Abstract: The present invention teaches all-natural formulations comprising amino acids for hair application. These formulations can be used for a wide range of hair treatments including hair detangling, hair curl loosening, hair straightening, for preventing hair breakage and stimulating hair growth. The methods used to generate the formulations are disclosed, along with the methods for treating hair with the formulations to attain one or more desired benefits.

Abstract: The present invention provides compositions utilizing a first zwitterionic ammonio-alkanamide and/or zwitterionic ammonio-alkanoate surfactant according to Formula 1 and an ingredient selected from the group consisting a surfactant other than the first zwitterionic surfactant, emulsifiers, conditioning agents, emollients, moisturizers, humectants, thickeners, lubricants, chelating agents, fillers, binding agents, anti-oxidants, preservatives, active ingredients, fragrances, dyes, buffering agents, exfoliates, pH adjusters, inorganic salts, solvents, viscosity controlling agents and opacifying agents, wherein the composition is substantially free of alkylamidoamine and aminoalkylamine.

Abstract: The present invention relates to a composition containing in an aqueous medium, at least: 1) an internal olefin sulfonate composition comprising: (A) an internal olefin sulfonate having 16 carbon atoms and (B) an internal olefin sulfonate having 18 carbon atoms, wherein a mass content ratio (A/B) of the component (A) to the component (B) contained in the sulfonate composition ton is from 75/25 to 90/10, and wherein a mass ratio (hydroxy form/olefin form) of a content of a hydroxy form in the internal olefin sulfonate of the component (A) and the component (B) to a content of an olefin form in the internal olefin sulfonate of the component (A) and the component (B) is from 75/25 to 100/0; and 2) at least one polymeric suspension agent.

Abstract: An oral supplement is provided comprising hyaluronic acid, probiotics, and xanthan gum.

Abstract: The present invention relates to an agent for oxidatively coloring or blonding hair that is gentle on the hair, and to a gentle method for oxidatively coloring or blonding hair, in which keratin fibers are protected from oxidative influences.

Abstract: The present invention relates to a process for preparing an anhydrous composition in powder form or in paste form, in which the following steps are performed: from 30% to 65% by weight, relative to the weight of the composition, of organic, mineral or composite solid particles, and also mixtures thereof, are prepared, 10% to 40% by weight, relative to the weight of the composition, of a mixture comprising at least one organopolysiloxane elastomer conveyed in at least a first silicone or hydrocarbon-based non-volatile oil is prepared, 10% to 45% by weight, relative to the weight of the composition, of an organic binder phase comprising at least a second hydrocarbon-based or silicone non-volatile oil, identical to or different from the first oil, is prepared; at least one pasty compound having a content of between 5% and 25% by weight, relative to the weight of the composition, optionally at least one wax and optionally at least one volatile oil; the wax content not exceeding 5% by weight, relative to the we

Abstract: An aqueous cosmetic composition includes: a) at least one alkyl glucoside including a linear or branched alkyl or alkenyl group having 14 to 30 carbon atoms and a mono-, di- or triglucoside group; b) at least one extract of a plant species from the aralia family (Araliaceae); c) at least one extract of a plant species from the pine family (Pinaceae); d) at least one extract of a plant species from the flowering plants family (Theaceae); and e) at least one extract of a plant species from the gooseberry family (Grossulariaceae).

Abstract: An object of the present invention is to provide hyaluronidase inhibitors, collagenase inhibitors, elastase inhibitors, MMP-1 production suppressors, and collagen synthesis promoters that contain as an active component one or more pigment compounds that are obtained as extracted from plants of the family Rosaceae, as well as agents for cutaneous application, skin cosmetics, and quasi-drugs that contain such pigment compounds. The present invention provides hyaluronidase inhibitors, collagenase inhibitors, elastase inhibitors, MMP-1 production suppressors, collagen synthesis promoters, agents for cutaneous application, skin cosmetics, and quasi-drugs that contain one or more compounds in a class of rosacyanins or one or more compounds in a class of rosadelphins as an active component.

Abstract: This invention relates to a skin-penetrating skin-care product, which is made of natural, raw ingredients including, among other things, plants, algae and fungi. Skin-care products are generally composed of highly processed components and they often comprise only few isolated nutrients. This invention intends to solve the problem of lack of quality and quantity of nutrients in the skin-care products.

Abstract: The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention.

Abstract: The present invention is directed to sublingual epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering sublingual epinephrine spray formulations to subjects in need of such treatments.

Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery, e.g., for affecting mood states. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Abstract: The present invention provides for compositions comprising a polymeric hydrogel impregnated with a toxin-absorbing or binding nanoparticle. The present invention also provides for the use of the above compositions for decreasing or neutralizing the effect of a toxin, or for treating or preventing an infection by a microbe that produces a toxin, in a subject. The exemplary toxin is a biological toxin such as a viral, bacterial, fungal, plant or animal toxin.

Abstract: The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.

Abstract: A pharmaceutical composition comprising bisacodyl [4,4?-(pyridine-2-ylmethylene)bis(4,1-phenylene) diacetate], a solvent, a buffer, and a polymer, methods and apparatus for delivery to a patient.

Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

Abstract: A solid dispersion for achieving improved solubility and absorbability of a pharmaceutically active ingredient, which contains (1) an amorphous pharmaceutically active ingredient, (2) one or more substances selected from among methyl cellulose and organic acids and (3) an enteric base material. In cases where methyl cellulose is contained therein, the solid dispersion does not contain any water-soluble polymer other than methyl cellulose.

Abstract: Compositions and methods for modified dendrimer nanoparticle (“MDNP”) delivery of therapeutic, prophylactic and/or diagnostic agent such as large repRNA molecules to the cells of a subject have been developed. MDNPs efficiently drive proliferation of antigen-specific T cells against intracellular antigen, and potentiate antigen-specific antibody responses. MDNPs can be multiplexed to deliver two or more different repRNAs to modify expression kinetics of encoded antigens and to simultaneous deliver repRNAs and mRNAs including the same UTR elements that promote expression of encoded antigens.

Abstract: A biocomposite powder comprising 20-95% (w/w) chitin-glucan complex (CGC), and up to 50% (w/w) mannose-containing polysaccharides, wherein the biocomposite powder has a bulk density of 0.5 to 1.0 g/cm3, and wherein greater than 60% (w/w) of the particles of the biocomposite powder have a size below 212 ?m.

Abstract: The present invention is directed to vaccination composition comprising a particle comprising a polymer matrix incorporating an adjuvant and/or an antigen, to method of making them and use. Particularly, the present invention results in adjuvants and/or antigens, covalently entrapped in or coupled to polymer carriers or polymeric devices, such as micelles, nanoparticles, microspheres and other types of polymer devices for controlled release; the adjuvant and/or antigen are covalently bonded in or to the polymer carriers or polymeric devices.

Abstract: Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.

Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.

Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

Abstract: Opioid controlled release formulation resistant to alcohol extraction of the opioid.

Abstract: Drug delivery formulations, uses thereof and methods of making same are provided in order to reduce the potential for abuse, misuse or improper administration of an addictive substance or any active substance and to prevent, reduce, inhibit, or delay purposeful or accidental overdose of an active substance by ingesting too many dosage forms at once, for example.

Abstract: Drug delivery formulations, uses thereof and methods of making same are provided in order to reduce the potential for abuse, misuse or improper administration of an addictive substance or any active substance and to prevent, reduce, inhibit, or delay purposeful or accidental overdose of an active substance by ingesting too many dosage forms at once, for example.

Abstract: The present invention provides compositions, devices; and methods for affecting, among other things, weight loss and/or weight control, by sequestering nutrients or other compounds such as toxins from absorption in the digestive tract. The compositions, devices, and methods employ one or more members made of a compressible, absorbent matrix material. In various embodiments, the matrix material is suitable for routine use. The compressible absorbent matrix material has a size, shape and/or geometry configured for efficient packing into a small space, and/or configured to absorb and substantially retain digested material in the stomach. The devices and compositions may further comprise one or more hydrogel(s), soluble or insoluble fibers, waxes and/or gums to provide the desired mechanical properties and/or absorptive or shielding properties.

Abstract: The present invention relates to a modified release coated capsule and a process to obtain that capsule.

Abstract: Disclosed is a copolymer of following formula (I): in which:—x is an integer between 10 and 250, preferably between 40 and 120, —y is an integer between 4 and 100, preferably between 10 and 100, preferably between 19 and 60, —z is an integer between 0 and (100?y), preferably equal to 0, —R represents an alkyl radical having 1 to 10 carbon atoms, a phospholipid, a glycosaminoglycan or an affinity ligand, and —R? represents a hydrogen, the —CH2—C?CH group, a —CH2-1H-1,2,3-triazole group, a —CH2—CH2—CH2—S—R? group, in which R? represents an alkyl radical having 1 to 10 carbon atoms, a phospholipid, a glycosaminoglycan, an affinity ligand or an imaging probe, and the uses of same.

Abstract: Present invention provides fully or partially biodegradable drug delivery product for controlled delivery of drugs. In one embodiment, the present invention relates to a drug delivery product having a shell comprising a first material and a second material, wherein the second material comprises a first biodegradable material; a core comprising a drug, the core being enclosed by the shell; wherein the first material is distributed in a matrix of the first biodegradable material; wherein the first material is configured to create holes in the shell; wherein the holes allow the drug to be released to the exterior of the shell through the holes.

Abstract: A nano- or micro-scale therapeutic agent is provided for use in the treatment of an infection of a human or animal. The agent includes micro- and/or nano-particle carriers loaded with at least one inert precursor chemical. The carriers encapsulate the precursor which after release from the carrier are activatable by the physiological milieu in situ at the site of the infection to form an antimicrobial agent. Preferably, the precursor chemical or chemicals form an oxidative biocide on release, which oxidative biocide is hydrogen peroxide. Advantageously, the precursor chemicals also include an acetyl donor that on release reacts with the hydrogen peroxide to produce a mixture of peracetic acid and hydrogen peroxide. The carrier is preferably in the form of micro- and/or nano-particles that have been manufactured using a thermally induced phase separation (TIPS) process, for example the carrier may be a biodegradable polymer such as poly(lactic-co-glycolic acid) (PLGA).

Abstract: Adhesive tapes are disclosed that have a flexible backing conformable to a body part and have a top surface and a bottom surface and a layer of an adhesive composition disposed on the bottom surface of the flexible backing. The adhesive composition is formed from a pressure sensitive adhesive, and a copper metal powder and/or copper metal flakes having an apparent density in the range of 1 g/ml to 4 g/ml suspended throughout the adhesive composition, and may include a thickening agent.

Abstract: Use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, wherein the inner phase comprises the additive and an active agent dissolved therein, wherein the additive has a higher affinity to water than to the active agent, for the control of the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, wherein the maintenance of the permeation rate is proportional to the amount of active agent in the biphasic layer.

Abstract: Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness. In particular extracts of cannabis plants are presented which are rich in these substances and suitable for pharmaceutical use.

Abstract: The present invention includes a composition and method for treating a glioblastoma in a human or animal subject comprising the steps of: identifying the human or animal subject in need of treatment of a glioblastoma, wherein the human or animal is no longer responsive to at least one of chemotherapy, surgery, or radiation therapy; and administering to the human or animal subject a therapeutically effective amount of a composition comprising: an amount of a curcumin or curcuminoids in one or more liposomes, or curcumin or curcuminoids and empty liposomes and administered prior to, concomitantly, or after administration of the curcumin or curcuminoids, that is effective for treating the glioblastoma, wherein the liposomal curcumin or curcuminoids, or empty liposomes, eliminate the QT prolongation caused by the curcumin or curcuminoids; and at least one chemotherapeutic agent that is synergistic with curcumin to treat the glioblastoma.

Abstract: A nutritional composition promotes musculoskeletal health in patients with inflammatory bowel disease. The nutritional composition contains casein protein, vitamin D, alpha-linolenic acid, and vitamin K in a ratio of vitamin K1:vitamin K2 between 3:1 to 1:3 and the vitamin K providing between 3.5-20 ?g/100 cal of the nutritional composition. A pharmaceutical formulation, a nutritional formulation, a tube-feed formulation, a dietary supplement, a functional food, a beverage product or a combination thereof comprising the nutritional composition is also disclosed. A method for improving musculoskeletal health is also disclosed.

Abstract: Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described herein.

Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) and other CNS stimulant responsive conditions include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by an extended release.